STOCK TITAN
  1. Home
  2. News
  3. LYEL

Lyell Immunopharma Inc - LYEL STOCK NEWS

Welcome to our dedicated news page for Lyell Immunopharma (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lyell Immunopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lyell Immunopharma's position in the market.

News
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
Rhea-AI Summary
Lyell Immunopharma, Inc. (LYEL) announced the acceptance of three abstracts for presentation at the AACR Annual Meeting 2024. The abstracts include data on Lyell's rejuvenation technology, LYL119 CAR T-cell therapy, and tumor-restricted IL-12 technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
none
-
News
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Rhea-AI Summary
Lyell Immunopharma, Inc. (LYEL) reported financial results and business highlights for Q4 and FY 2023. They are on track to report initial clinical data in 2024, received Orphan Drug Designation for LYL845, and plan to submit an IND for a new CAR T-cell product. Cash position of $562.7 million supports operations into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
earnings
-
News
Lyell Immunopharma Announces Participation in March Investor Conferences
Rhea-AI Summary
Lyell Immunopharma, Inc. (LYEL) will be presenting at TD Cowen's 44th Annual Health Care Conference and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. The company is a clinical-stage T-cell reprogramming firm with a pipeline of cell therapies for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.78%
Tags
none
News
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lyell Immunopharma, Inc. (Nasdaq: LYEL) to present at 42nd Annual J.P. Morgan Healthcare Conference, showcasing their diverse pipeline of cell therapies for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
Rhea-AI Summary
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced that the FDA granted Orphan Drug Designation to LYL845, a TIL product candidate for stage IIB-IV melanoma treatment, with potential for better outcomes in other solid tumors. Initial clinical data from the Phase 1 trial are expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.43%
Tags
clinical trial
-
News
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
Rhea-AI Summary
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reports financial results and business highlights, extending funding into 2027, with cash, cash equivalents, and marketable securities of $598.2 million as of September 30, 2023. They remain on track to release initial clinical data from two clinical-stage product candidates in 2024 and have entered into a manufacturing collaboration with Cellares for a CAR T cell product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
earnings
News
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Rhea-AI Summary
Lyell Immunopharma, Inc. is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The presentations focus on innovations to shorten tumor infiltrating lymphocyte (TIL) manufacturing, new nonclinical data on LYL119, new technologies, and the design of two clinical trials in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.54%
Tags
clinical trial
-
News
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Rhea-AI Summary
Lyell Immunopharma, Inc. (Nasdaq: LYEL) will present six abstracts at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), highlighting their clinical and preclinical product candidates and a shortened TIL manufacturing process. The presentations will include new nonclinical data on product candidates and emerging technologies, as well as updates on ongoing Phase 1 clinical trials. Notable presentations include a new technology collaboration with Outpace to enhance solid tumor T cell therapies and a Phase 1 trial evaluating a ROR1-targeted CAR T-cell therapy in patients with triple-negative breast cancer and non-small cell lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
-
News
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Rhea-AI Summary
Cellares and Lyell collaborate to evaluate Cellares' automated manufacturing platform for CAR T-cell therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
none
News
Lyell Immunopharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Lyell Immunopharma, Inc. to participate in upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
Stock LYEL logo
Lyell Immunopharma Inc

Nasdaq:LYEL

LYEL Rankings

#2873 Ranked by Market Cap
#5203 Ranked by Stock Gains
N/A Ranked by Dividends

LYEL Stock Data

764.83M
163.35M
15.59%
72.88%
7.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About LYEL

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.